Research programme: opioid mu receptor antagonists - Merck

Drug Profile

Research programme: opioid mu receptor antagonists - Merck

Alternative Names: ADL 5510

Latest Information Update: 08 Feb 2017

Price : $50

At a glance

  • Originator Adolor Corporation
  • Class Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyskinesias

Most Recent Events

  • 16 Dec 2011 Discontinued - Preclinical for Dyskinesia in USA (PO)
  • 12 Dec 2011 Adolor Corporation has been acquired and merged into Cubist Pharmaceuticals
  • 05 Nov 2010 Adolor Corporation receives grant from the Michael J. Fox Foundation for opioid mu receptor antagonist development in Levodopa-induced dyskinesia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top